 | Up a level |
Journal Article
Gluz, Oleg, Scheffen, Iris, Degenhardt, Tom, Marschner, Norbert Walter, Christgen, Matthias, Kreipe, Hans Heinrich, Nitz, Ulrike, Kates, Ronald E., Schinkoethe, Timo, Graeser, Monika Karla, Wuerstlein, Rachel, Kuemmel, Sherko 
ORCID: 0000-0001-9355-494X, Bauer, Lelia, Schem, Christian, Fehm, Tanja N., Neubauer, Hans and Harbeck, Nadia
(2021).
ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker-Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2-early breast cancer.
J. Clin. Oncol., 39 (15).
PHILADELPHIA:
LIPPINCOTT WILLIAMS & WILKINS.
ISSN 1527-7755
Wirtz, Ralph M., Scheffen, Iris, Marme, Frederik, Laible, Mark, Schlombs, Kornelia, Hake, Roland, Schumacher, Claudia, Schneeweiss, Andreas, Eidt, Sebastian and Sinn, Hans-Peter ORCID: 0000-0003-2836-6699
(2016).
Predictive value of ultra-high ESR1 mRNA expression in early breast cancer.
J. Clin. Oncol., 34 (15).
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 1527-7755